Jin-xing S. Zhang

No. 300 Guangzhou Road
Nanjing, 210029, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Dual-energy computed tomography venography parameters as potential indicators for pulmonary embolism in deep vein thrombosis.

Dual-energy computed tomography venography parameters as potential indicators for pulmonary embolism in deep vein thrombosis.

Journal: Journal of thoracic disease

Published: January 26, 2026

Comparison of short-term changes in right ventricular function after catheter-directed thrombolysis-based therapy vs. anticoagulation alone in acute intermediate-risk pulmonary embolism.

Comparison of short-term changes in right ventricular function after catheter-directed thrombolysis-based therapy vs. anticoagulation alone in acute intermediate-risk pulmonary embolism.

Journal: Journal of thoracic disease

Published: November 26, 2025

The characteristics of upper lobe-origin hemoptysis: analysis based on 31 patients.

The characteristics of upper lobe-origin hemoptysis: analysis based on 31 patients.

Journal: Journal of thoracic disease

Published: September 11, 2025

CT-Based Habitat Model for Predicting Tumor Response and Survival in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Combining Molecular Targeted Agents and Immune Checkpoint Inhibitors.

CT-Based Habitat Model for Predicting Tumor Response and Survival in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Combining Molecular Targeted Agents and Immune Checkpoint Inhibitors.

Journal: Academic radiology

Published: July 10, 2025

Artificial intelligence in digital pathology diagnosis and analysis: technologies, challenges, and future prospects.

Artificial intelligence in digital pathology diagnosis and analysis: technologies, challenges, and future prospects.

Journal: Military Medical Research

Published: May 11, 2025

MRI-Based Quantification of Intratumoral Heterogeneity Predicts Response in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab and TACE/HAIC.

MRI-Based Quantification of Intratumoral Heterogeneity Predicts Response in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab and TACE/HAIC.

Journal: Academic radiology

Published: April 01, 2025

Increment of Skeletal Muscle Mass Predicts Survival Benefit for Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Combining Molecular Targeted Agents and Immune Checkpoint Inhibitors.

Increment of Skeletal Muscle Mass Predicts Survival Benefit for Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Combining Molecular Targeted Agents and Immune Checkpoint Inhibitors.

Journal: Journal of hepatocellular carcinoma

Published: November 13, 2024

Transarterial chemoembolization combined with molecular targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma beyond the up-to-seven criteria: a propensity score-matching analysis.

Transarterial chemoembolization combined with molecular targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma beyond the up-to-seven criteria: a propensity score-matching analysis.

Journal: Annals of medicine

Published: November 01, 2024

Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study.

Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study.

Journal: Journal of hepatocellular carcinoma

Published: June 11, 2024

Efficacy and Safety of TACE Combined with a Tyrosine Kinase Inhibitor for the Treatment of TACE-Refractory Hepatocellular Carcinoma: A Retrospective Comparative Study.

Efficacy and Safety of TACE Combined with a Tyrosine Kinase Inhibitor for the Treatment of TACE-Refractory Hepatocellular Carcinoma: A Retrospective Comparative Study.

Journal: Journal of gastrointestinal cancer

Published: March 02, 2024

Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.

Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.

Journal: Cardiovascular and interventional radiology

Published: December 10, 2023

Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.

Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.

Journal: Academic radiology

Published: July 08, 2023

Showing 1-12 of 30

Last Updated: 09/26/2026